Q-Gen Cell Therapeutics is a fully integrated GMP manufacturing facility with the capacity to translate QIMR Berghofer’s clinical research to the bedside.
These facilities are also available for external researchers and commercial organisations requiring cleanroom facilities. Partnering with leading biotech and pharma companies, Q-Gen Cell Therapeutics has an impressive track record in adoptive T cell therapies for Phase I and Phase II clinical trials.
The Q-Gen facility has 1,000 m² of dedicated floor space, comprising of an in-house quality control testing laboratory, office space, storage rooms and up to 13 cleanrooms, available to meet ISO Class 7 and PC2 standard, with dedicated air handling units for the majority of rooms. Q-Gen Cell therapeutics can also provide a range of cell processing and research equipment, maintained and validated for GMP use. All critical equipment is continuously connected to an independent backup power generator, which includes 24 hr monitoring and recording of the equipment parameters, through our building management system.
genomiQa offers hospitals, clinicians, researchers, and biopharma companies high-quality analysis of data from whole genome sequencing. We bring precision analytics to routine clinical practice. In practice this offers:
- More accurate diagnostics
- Better decision support for clinicians
- Precision drug development
genomiQa is a start-up company that has grown out of the QIMR Berghofer Medical Research Institute—now a major shareholder and where genomiQa is based. Founders, Dr Nic Waddell and John Pearson, have more than 35 years’ combined experience in genomics and bioinformatics. These areas of expertise blend powerfully within genomiQa’s products and services, which are designed to support personalised treatment and better outcomes for patients.
Q-Pharm conducts early phase (Phases 1 and 2) clinical trials, bioequivalence & bioavailability studies and vaccine studies.
These studies are conducted in a state-of-the-art 62-bed facility within the QIMR Berghofer precinct at the Royal Brisbane and Women’s Hospital, Brisbane, Australia. The company provides a comprehensive, high-quality service to clients, and conducts all trials in accordance with all applicable national and international standards and guidelines. Q-Pharm’s strength is its highly-qualified clinical trial team, whose leaders have a wealth of experience in clinical development. This experience enables Q-Pharm to understand the needs of our diverse range of clients and thereby deliver on time the highest quality clinical services to satisfy client needs.
BGI focuses on genomic research and applications in the healthcare, agriculture, conservation, and environmental fields, and has become the largest genomic organization in the world.
Due to BGI's growing presence and influence in the world, BGI Australia was established in August 2016 to support its growth in the Asia-Pacific region, with an office in the prestigious QIMR Berghofer Medical Research Institute in Herston, Brisbane. BGI Australia utilises a proprietary, world-leading sequencing platform and boasts superb bioinformatical analysis capabilities. BGI Australia has established collaborations with leading research institutions in the region to carry out scientific research and innovative projects in relation to human medicine, health science, sports science, marine science, biodiversity, and agriculture. The QIMR Berghofer Business Development team identifies innovative research projects that can be directed towards commercialisation using the genomic expertise of BGI Australia.